LEADS BIOLABS-B(09887): LBL-034(GPRC5D/CD3 bispecific T-CELL ENGAGERTCE) is granted Fast Track designation by the U.S. FDA.

08:38 28/01/2026

Weidi Zhibo-B (09887) announced on January 27, 2026 that LBL-034 (GPRC5D/CD3 bispecific antibody) has been granted Fast Track Designation ("FTD") by the U.S. Food and Drug Administration ("FDA") for the treatment of relapsed/refractory multiple myeloma ("RRMM").

LEADS BIOLABS-B(09887) announced that on January 27, 2026, LBL-034 (GPRC5D/CD3 bispecific antibody) was granted Fast Track Designation (FTD) by the Food and Drug Administration ("FDA") in the United States for the treatment of relapsed/refractory multiple myeloma ("RRMM").

HK Stock Market Move | Chip stocks are performing strongly, with AI driving prices up across the entire semiconductor industry chain. Two semiconductor companies have officially announced price increases.

HK Stock Market Move | Vincent Med's share price rose by more than 9% after the profit announcement. It is expected that the shareholders' comprehensive profit for the fiscal year 2025 will be no less than HK$100 million.

New Stock News | Delton Technology (001389.SZ) Hong Kong Stock IPO approved by China Securities Regulatory Commission